Huntington National Bank’s Neurocrine Biosciences NBIX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $93.8K | Buy |
712
+34
| +5% | +$4.51K | ﹤0.01% | 1101 |
|
|
2025
Q4 | $96.2K | Buy |
678
+76
| +13% | +$11K | ﹤0.01% | 992 |
|
|
2025
Q3 | $84.5K | Sell |
602
-2
| -0.3% | -$271 | ﹤0.01% | 1045 |
|
|
2025
Q2 | $75.9K | Buy |
604
+126
| +26% | +$14.4K | ﹤0.01% | 1079 |
|
|
2025
Q1 | $52.9K | Buy |
478
+249
| +109% | +$31.5K | ﹤0.01% | 1158 |
|
|
2024
Q4 | $31.3K | Buy |
229
+97
| +73% | +$12K | ﹤0.01% | 1394 |
|
|
2024
Q3 | $15.2K | Buy |
132
+45
| +52% | +$6.17K | ﹤0.01% | 1607 |
|
|
2024
Q2 | $12K | Buy |
87
+24
| +38% | +$3.29K | ﹤0.01% | 1628 |
|
|
2024
Q1 | $8.69K | Buy |
63
+13
| +26% | +$1.77K | ﹤0.01% | 1727 |
|
|
2023
Q4 | $6.59K | Sell |
50
-5
| -9% | -$576 | ﹤0.01% | 1793 |
|
|
2023
Q3 | $6.19K | Buy |
55
+18
| +49% | +$1.9K | ﹤0.01% | 1733 |
|
|
2023
Q2 | $3.49K | Sell |
37
-10
| -21% | -$977 | ﹤0.01% | 1919 |
|
|
2023
Q1 | $4.76K | Buy |
47
+46
| +4,600% | +$4.79K | ﹤0.01% | 1739 |
|
|
2022
Q4 | $119 | Hold |
1
| – | – | ﹤0.01% | 2046 |
|
|
2022
Q3 | $1K | Hold |
1
| – | – | ﹤0.01% | 1939 |
|
|
2022
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 2283 |
|
|
2022
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 2244 |
|
|
2021
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 2201 |
|
|
2021
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 1943 |
|
|
2021
Q2 | $0 | Hold |
1
| – | – | ﹤0.01% | 1857 |
|
|
2021
Q1 | $0 | Hold |
1
| – | – | ﹤0.01% | 1748 |
|
|
2020
Q4 | $0 | Hold |
1
| – | – | ﹤0.01% | 1711 |
|
|
2020
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 1670 |
|
|
2020
Q2 | $0 | Sell |
1
-433
| -100% | -$47.9K | ﹤0.01% | 1664 |
|
|
2020
Q1 | $38K | Hold |
434
| – | – | ﹤0.01% | 867 |
|
|
2019
Q4 | $47K | Buy |
434
+433
| +43,300% | +$45.3K | ﹤0.01% | 963 |
|
|
2019
Q3 | $0 | Hold |
1
| – | – | ﹤0.01% | 1679 |
|
|
2019
Q2 | $0 | Buy |
+1
| New | +$82 | ﹤0.01% | 1723 |
|
|
2016
Q4 | – | Sell |
-28
| Closed | -$1K | – | 1479 |
|
|
2016
Q3 | $1K | Sell |
28
-3
| -10% | -$149 | ﹤0.01% | 1487 |
|
|
2016
Q2 | $1K | Buy |
+31
| New | +$1.43K | ﹤0.01% | 1453 |
|
|
2016
Q1 | – | Sell |
-32
| Closed | -$2K | – | 1787 |
|
|
2015
Q4 | $2K | Buy |
32
+3
| +10% | +$152 | ﹤0.01% | 1563 |
|
|
2015
Q3 | $1K | Buy |
29
+13
| +81% | +$628 | ﹤0.01% | 1688 |
|
|
2015
Q2 | $0 | Buy |
+16
| New | +$678 | ﹤0.01% | 1804 |
|
Other funds holding NBIX
VPM
VCM
Huntington National Bank's NBIX Position: Q1 2026 in Review
Huntington National Bank increased its Neurocrine Biosciences (NBIX) stake by 5% in Q1 2026, buying an estimated $4.51K and bringing the position to 712 shares worth $93.8K. The position accounts for ﹤0.01% of the portfolio, ranked #1101.
Huntington National Bank first reported a position in NBIX in Q2 2015 and has held it in 33 quarters since. The position peaked at $96.2K in Q4 2025. 695 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.
- Huntington National Bank held 712 shares of Neurocrine Biosciences worth $93.8K as of Q1 2026.
- Huntington National Bank bought 34 Neurocrine Biosciences shares in Q1 2026, an estimated $4.51K.
- Neurocrine Biosciences made up ﹤0.01% of Huntington National Bank's portfolio in Q1 2026, its #1101 holding.
- Huntington National Bank first reported a position in Neurocrine Biosciences in Q2 2015 and has held it in 33 quarters since.
- Huntington National Bank's Neurocrine Biosciences position peaked at $96.2K in Q4 2025.
- 695 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.
Based on Huntington National Bank's 13F filing for Q1 2026, filed 15 May 2026.